Leiomyosarcoma of the corpus uteri

Leiomyosarcoma of the corpus uteri (uterine leiomyosarcoma, ULMS) is a rare and aggressive malignant tumor arising from the smooth muscle cells of the uterine body (myometrium). It is the most common uterine sarcoma, accounting for approximately 1-2% of all uterine malignancies. Unlike benign uterine leiomyomas (fibroids), which are extremely common, leiomyosarcomas are cancerous and have a propensity for early hematogenous spread, most frequently metastasizing to the lungs, liver, and peritoneal cavity. The disease primarily affects the reproductive system but can impact multiple organ systems through metastatic spread. Key clinical features include abnormal uterine bleeding (the most common presenting symptom), a rapidly enlarging pelvic mass, pelvic pain or pressure, and occasionally vaginal discharge. Many cases are diagnosed incidentally after hysterectomy or myomectomy performed for presumed benign fibroids, as preoperative distinction between leiomyomas and leiomyosarcomas remains challenging even with advanced imaging techniques. The primary treatment for localized uterine leiomyosarcoma is surgical, typically involving total hysterectomy with or without bilateral salpingo-oophorectomy. The role of lymph node dissection remains debated. For advanced or recurrent disease, treatment options include chemotherapy (commonly doxorubicin, gemcitabine with docetaxel, or trabectedin), targeted therapies, and radiation therapy, though the tumor is generally considered relatively resistant to radiation. The prognosis is often poor compared to other uterine malignancies, with five-year survival rates varying significantly by stage at diagnosis. Ongoing research is exploring novel targeted agents and immunotherapy approaches to improve outcomes for patients with this challenging malignancy.

Common questions about Leiomyosarcoma of the corpus uteri